Venture Visionary Partners LLC Has $1.06 Million Stock Position in Danaher Corporation $DHR

Venture Visionary Partners LLC lowered its stake in Danaher Corporation (NYSE:DHR) by 42.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,169 shares of the conglomerate’s stock after selling 3,837 shares during the quarter. Venture Visionary Partners LLC’s holdings in Danaher were worth $1,060,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Bank Pictet & Cie Europe AG grew its position in shares of Danaher by 22.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate’s stock valued at $44,241,000 after purchasing an additional 35,730 shares during the last quarter. First Trust Advisors LP grew its position in shares of Danaher by 13.6% in the fourth quarter. First Trust Advisors LP now owns 37,854 shares of the conglomerate’s stock valued at $8,689,000 after purchasing an additional 4,519 shares during the last quarter. Transce3nd LLC acquired a new position in shares of Danaher in the fourth quarter valued at approximately $49,000. OneDigital Investment Advisors LLC grew its position in shares of Danaher by 46.6% in the fourth quarter. OneDigital Investment Advisors LLC now owns 16,742 shares of the conglomerate’s stock valued at $3,843,000 after purchasing an additional 5,325 shares during the last quarter. Finally, MGO One Seven LLC grew its position in shares of Danaher by 1.3% in the fourth quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate’s stock valued at $984,000 after purchasing an additional 53 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Down 0.4%

Shares of DHR stock opened at $211.2470 on Thursday. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock has a market cap of $151.26 billion, a P/E ratio of 44.95, a price-to-earnings-growth ratio of 2.96 and a beta of 0.73. The stock has a 50 day simple moving average of $200.46 and a 200 day simple moving average of $199.62. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. During the same period in the prior year, the company earned $1.72 earnings per share. The company’s quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DHR. Evercore ISI decreased their target price on Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. TD Cowen upped their target price on Danaher from $240.00 to $248.00 and gave the company a “buy” rating in a research report on Wednesday, April 23rd. Barclays reaffirmed an “overweight” rating and issued a $225.00 target price (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price target for the company in a research note on Friday, July 11th. Finally, Wells Fargo & Company cut their price target on Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average price target of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.